Plus   Neg

Stock Alert: OptiNose Up 17%

Shares of OptiNose, Inc. (OPTN) jumped over 17% on Tuesday morning after pharmaceutical company announced an anti-COVID-19 product candidate.

OPTN is currently trading at $7.56, up $1.14 or 17.76%, on the Nasdaq.

Optinose initiated the development of a new product candidate, OPN-019, which combined with the company's nasal Exhalation Delivery System (EDS) technology with an antiseptic is expected to kill the virus that causes COVID-19.

The company said it expects to be able to rapidly progress to a meeting with FDA to discuss an IND and then onward to clinical trials, as components of the drug-device combination product candidate, including both the active drug and delivery device, are currently commercially available in the U.S.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Department of Health and Human Services or HHS said it has secured most of the supply of COVID-19 drug remdesivir through September. The deal would allow American hospitals to purchase the antiviral drug in allocated amounts amid the spike in confirmed cases each day. HHS Secretary Alex Azar said, "President Trump has struck an amazing deal to ensure Americans have access to the first..." Novartis AG (NVS) agreed to pay $678 million to settle U.S. government charges it paid illegal kickbacks to doctors to induce them to prescribe its cardiovascular and diabetes drugs, the U.S. Department of Justice said in a statement. PG&E Corp. (PCG) said Wednesday that it has emerged from Chapter 11 bankruptcy protection, after implementing its financial restructuring plan that was previously approved by the U.S. Bankruptcy Court and state regulators.
Follow RTT